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A sclerosis multiplex (SM) komplex genetikai betegség,
melyet több gén határoz meg környezeti faktorokkal történô
kölcsönhatásban. A hajlamosító variánsok átfogó
feltárására csak nemrégen kerülhetett sor, amikor az új
biotechnológiai és bioinformatikai fejlôdés eredményeként
lehetôvé vált a teljes humán genom szekvenciájának
meghatározása, a polimorf variánsok katalogizálása és a
variánsok haplotípusokba való sorolása. 
Korábbi epidemiológiai, jelölt gén és kapcsoltsági tanul-
mányok alátámasztották az SM komplex genetikai
meghatározottságát. Az új biotechnológiai és bioinfor-
matikai eszközök kiaknázása az SM további sikeres
feltárásához vezetett. Ezeket az erôfeszítéseket kiegészítette a
betegség fenotípusának megbízható meghatározása, a spe-
cializált SM-központok közötti kollaborációk kialakítása a
megfelelô mintaszám elérése érdekében és olyan alapku-
tató-klinikusok bevonása a tanulmányokba, akik képesek
klinikai és alaptudományi feladatokat is ellátni. A teljes
genom asszociációs tanulmányokból nyert adatok az SM
megértését új szintre emelték a genetikai determinánsok
átfogó azonosításával. A betegséggel asszociálódó variációk
biológiai összefüggéseinek elemzésébôl meggyôzô
bizonyítékot nyertünk az SM immuneredetét illetôen. A
közeljövôben valószínûleg olyan megközelítések vezethetnek
az SM további megértéséhez, melyek feltárják, hogy a
környezeti faktorok milyen módon állnak kölcsönhatásban a
genommal és eredményeznek abnormális immunaktivációt,
valamint gyulladást.
Ez az áttekintés összegzi az SM genetikai tanulmányok,
köztük a teljes genom asszociációs tanulmányok ered-
ményeit, és kiemeli a genetikai/genomikai tanulmányok
gyakorlati jelentôségét abban, milyen módon segíthetik ezen
adatok az SM kialakulásának jobb megértését. A betegség
kórfolyamatának jobb megértése a terápiás megközelítések
jövôbeli fejlôdésének és új megelôzô stratégiák kialakításá-
nak kulcsa lehet.     
Kulcsszavak: komplex trait, nukleotida-pontpolimorfizmus,
haplotípus, teljes genom asszociációs tanulmány, 
biológiai kórfolyamat elemzése
Multiple sclerosis (MS) is a complex trait disorder defined by
several genes and their interactions with environmental fac-
tors. A comprehensive exploration of the susceptibility vari-
ants had not been feasible until recently when new develop-
ments in biotechnology and bioinformatics made possible
sequencing of the whole human genome, cataloguing of
nucleotide variants and alignments of these variants in hap-
lotypes. 
Earlier observations from epidemiological, candidate gene
and linkage studies provided ample evidence to support a
complex genetic determination of MS. New biotechnology
and bioinformatics resources have been recently applied to
further successful explorations of the disease. These efforts
were paralleled by more careful and reliable ascertainments
of disease phenotypes, collaborations among specialized
centers to generate sufficient sample size and involvement of
clinician-scientists capable of working both on the clinical
and scientific study sides. Data obtained from the whole
genome association studies (GWAS) elevated our under-
standing of MS genetics to a new level by identifying an
extensive list of genetic determinants. Pathway analyses of
MS-associated variants provided evidence to support the
immune etiology of the disease. Future research will likely
explore how environmental factors interact with the genome,
and contribute to the abnormal immune activation and
inflammation. 
This review summarizes the outcomes of MS genetic explo-
rations including those of recent GWAS, and highlights prac-
tical consequences of genetic and genomic studies by point-
ing out as to how the derived data facilitate further
elucidation of MS pathogenesis. A better understanding of
disease processes is necessary for future advancements in
therapeutics and the development of disease prevention
strategies.
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Multiple sclerosis (MS) is characterized byinflammation, demyelination and neurode-
generation of the central nervous system (CNS).
The onset of the disease is typically in young adult-
hood, but may occur at any age from small child-
hood to late adulthood1. Presenting symptoms of
motor, visual, sensory, coordination, autonomous
and cognitive impairments may occur alone or in
combination. The diagnosis is established today
based on the McDonald’s criteria and its updated
versions2, 3, all with the core requirement to demon-
strate dissemination of pathology in time and space.
About 85% of MS patients have relapsing-remitting
course during the early phase the disease, while the
remaining 15% of patients have progressive course
with or without superimposed relapses from disease
onset. These two latter forms are referred to as pro-
gressive-relapsing and primary progressive MS,
respectively. Most patients with relapsing-remitting
disease onset will later develop secondary progres-
sive course. The older the age of relapsing-remit-
ting disease onset, the higher the probability and the
shorter the latency of conversion to secondary pro-
gressive disease1, 4.
Magnetic resonance (MR) imaging not only
made feasible to establish the diagnosis earlier and
with higher degrees of certainty, but also facilitated
gaining much insight into the disease pathogenesis.
MS is considered today a disease of the whole CNS,
with extensive microscopic pathology present not
only within but also outside of plaques, in the so
called “normal appearing” white and gray matter5.
This microscopic pathology includes small foci of
inflammation, demyelination, astrogliosis, micro -
glial activation and neuroaxonal degeneration along
with complex molecular alterations, and gives sig-
nal alterations when using specific MR sequences6.
These microscopic lesions are the precursors of
future macroscopic lesions. Plaques, that had been
considered the pathological hallmarks of MS, rep-
resent the most severely affected regions of inflam-
matory demyelination, neurodegeneration and reac-
tive gliosis. Most plaques are visible by the naked
eye in brain sections and visualized by convention-
al MR sequences in clinical routine. As a plaque
evolves, its appearances change from inflammatory
demyelination and tissue loss to a severe non-
inflammatory but rather degenerative and astrogli-
otic (sclerotic) lesion. Because of the progressive
loss of white and gray matter regions secondary to
inflammation and demyelination in the CNS, tissue
atrophy accumulates in the brain and spinal cord
from the earliest stages of MS5, 6. Brain atrophy and
lesion load strongly predict long term clinical dis-
ability7.
There has been a debate as to whether there is an
inter-individual heterogeneity (but intra-individual
homogeneity) of pathology or the heterogeneity
evolves over time during progressive lesion devel-
opment8, 9. Investigators representing the former
view suggest that acute demyelinating lesions of
MS may be grouped into four subclasses each con-
sistent in individual patients. These four subgroups
include lesions with 1) mononuclear inflammation,
2) mononuclear inflammation and immunoglobulin
plus complement deposition, 3) dying back oligo-
dendrocytopathy and apoptosis, and 4) other forms
of oligodendrocytopathy and necrosis8. Investiga -
tors representing the second view argue that the ear-
liest histological lesion involves oligodendrocyte
apoptosis and microglial activation in still myeli-
nated tissue with sparse mononuclear infiltration9.
Based on this observation, demyelination is preced-
ed by oligodendrocyte injury of unknown etiology,
and the infiltration by blood-borne mononuclear
cells may be secondary to the evolving CNS pathol-
ogy.
Oligodendrocyte and neuronal apoptosis as well
as the neurodegenerative changes, however, have
been interpreted in most studies as lesions develop-
ing secondary to inflammation, and may involve
oxidative damage to mitochondrial macromolecules
leading to mitochondrial mechanisms of tissue
loss10, 11. 
While recent development in in vivo and in vitro
imaging technologies facilitated to gain much
insight into the temporal evolution and molecular
characteristics of MS lesions, the causes of immune
activation and inflammation are not well under-
stood. Based on the abnormalities observed in the
peripheral immune system, MS has been considered
an autoimmune disease. The main immune effec-
tors of lesion development appear to be CD4+ T
helper (TH) subpopulations, specifically the TH-17
and TH-1 cells with distinct pro-inflammatory
cytokine profiles (interleukine[IL]-17and IL2,
interferon-gamma, respectively)12. In contrast, TH-
2 cells with IL-4 and IL-10 cytokine profiles may
exert protective regulatory effects. Monocytes,
macrophages, dendritic cells and B lymphocytes
present various antigens and contribute to the dif-
ferentiation and activation of TH-17/TH-1 cells13.
Immunoglobulins specific for myelin, axonal and
neuronal molecular components also may con-
tribute to the development of subtypes of lesions8,
14. While the disease-relevant antigenic determi-
nants remain to be determined, a deficiency in the
regulatory CD4+, CD25+, Foxp3+ Treg cells in the
peripheral circulation as well as in the brain seems
to play important roles in the abnormal immune
310 Kálmán: Multiple sclerosis genetics
kalman_UJ ISZ TUKOR ALAP ANGOL.qxd  2014.09.23.  16:20  Page 310
Az alábbi dokumentumot magáncélra töltötték le az eLitMed.hu webportálról. A dokumentum felhasználása a szerzôi jog szabályozása alá esik.
response15. Besides abnormalities in the adaptive
immune system (e.g. antigen specific CD4+ T
cells), functional deficiencies in the innate immune
system (e.g. natural killer cells) have also been
noted16. Evidence suggests the involvements of sev-
eral environmental factors (early microbial expo-
sures, vitamin D, UV, smoking, etc…) in the patho-
genesis of MS, which likely act through interactions
with the immune system and contribute to the
abnormal activation of T cells17. Nevertheless, the
exact role and temporal sequence of host-environ-
ment interactions in MS have not been sufficiently
clarified to unequivocally explain the etiology of
the disease. 
With the advancement in molecular technologies
and the successful exploration of the human
genome the hope arose that gaining deeper insights
into the characteristics of the genome, transcrip-
tome and epigenome of MS patients will clarify
ambiguities concerning the etiology of the disease
and facilitate our understanding of its pathogenesis.
This survey of genetic and genomic literature,
therefore, aims to summarize as to what we have
learnt from studying the genome and its products to
better explain the pathogenesis of MS and to identi-
fy new treatment targets. 
Genetic and genomic studies in 
multiple sclerosis
EPIDEMIOLOGY
Epidemiological studies investigate occurrence
(prevalence and incidence), geographic and ethnic
distribution, familial recurrence and environmental
determinants of a disease, and explore interactions
among host and environmental factors. Extensive
epidemiological studies have been conducted for
over a century in MS, and provided ample evidence
to support its genetic etiology, but with significant
environmental involvement. The genetic determi-
nation of the disease is supported by several obser-
vations. First, there are ethnic differences in the
occurrence of the disease even among populations
living next to each other in the same environ-
ment18–21. Second, the risk for monozygotic twin-
pairs is 300-times, and for first degree relatives of
MS patients is 20-40-times higher than for some-
one in the general population22–24. With the decrease
of relatedness, the risk for MS is also decreasing.
Third, half-sib studies, conjugal pairs and adoption
studies confirm that this increased risk exists only
for biological relatives25–27. Fourth, the inheritance
of MS is not compatible with mendelian (autosomal
dominant, recessive or X-linked) or mitochondrial
transmission patterns. MS is a complex trait defined
by interactions among several genes and environ-
mental factors11, 28. 
CASE-CONTROL CANDIDATE GENE ASSOCIATION STUDIES
Since the early 1970-ies, case-control association
studies have been conducted in increasing numbers,
as improving methods for defining polymorphic
alleles at the protein, RNA and DNA levels revea-
led more and more variants in candidate genes of
inflammation and demyelination11. These hypothe-
sis-driven association studies selected candidate
genes based on the autoimmune hypothesis of inf-
lammatory demyelination in MS, and statistically
tested the allele frequency differences within these
candidate genes in populations of sporadic cases
(patients) and controls, matched for age, gender and
ethnicity. Similar to most autoimmune diseases, the
involvement of the Human Leukocyte Antigen
(HLA) locus in MS is now unambiguously establis-
hed11, 29. Due to a strong linkage disequilibrium in
this region, however, it has been difficult to sort out
which allele of the HLA-DRB5*0101-HLA-
D R B 1 * 1 5 0 1 - H L A - D Q A 1 * 0 1 0 2 - H L A -
DQB1*0602 MS-associated extended haplotype
has the primary role in the disease30, 31. This exten-
ded haplotype confers a relative risk of =3 in indi-
viduals of Northern-European descent (meaning
that carriers of the haplotype have a 3X risk for MS
compared to non-carriers), but other DRB1 alleles
also play important roles in Northern-Europeans
and in other ethnic groups as well31. At the indivi-
dual level, epistatic interactions occur among DRB1
susceptibility and resistance allele combinations
and contribute to a fine tuning of the overall risk for
the disease31. Alleles of non-DRB1 HLA genes (e.g.
HLA A3 predisposing and HLA A2 protective alle-
les) also may modify susceptibility to the disea-
se32–35. Thus, both HLA allelic (e.g. alleles of the
DRB1 gene) and locus (e.g. HLA A locus or HLA
DR locus) heterogeneity seem to play roles in defi-
ning MS susceptibility. Hypothesis driven, case-
control studies also tested allele frequency differen-
ces in non-HLA candidate genes involved in
immune response and demyelination/remyelinati-
on, but revealed less unambiguous associations due
to the small effects of these genes, heterogeneity of
the disease and often insufficient sample sizes11.
LINKAGE ANALYSES
The method of linkage became very successful in
identifying disease loci with subsequent cloning of
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disease-relevant genes in mendelian disorders
(caused by highly pathogenic mutation[s] in single
genes) from the early 1990-ies. Because of the
strong effect of such a mutation, analyzing one or a
few large families with multiple affected members
usually was sufficient in mendelian disorders. In
contrast, the polymorphic genetic variants (not
pathogenic mutations) that define complex trait dis-
orders exert small effects, and therefore, several
hundreds of families are needed for a linkage study
to have statistical outcome. Generally in linkage
studies, polymorphic microsatellite markers are
genotyped in multiple affected and unaffected indi-
viduals in families with more than one patient, and
the segregation of microsatellite alleles with the dis-
ease trait is determined. Microsatellites are short, 2-
6 base pairs sequence repeats. The numbers of these
repeats result in length variations and define the
microsatellite alleles, which are inherited. The first
genome-wide linkage analyses using microsatellite
markers in MS were published in 199636–38. These
studies identified several loci, each with moderate
lod scores, suggesting potential relevance to the dis-
ease, and those which were identified in more than
one study, particularly attracted attention for follow
up. Since then, numerous linkage analyses, with
varying degrees of coverage and in families of vary-
ing ethnicity, have been carried out29. However, this
approach revealed that linkage is not the ideal tool
to study complex disorders (as opposed to
mendelian disorders), due to the weak signals of
genes and the genetic heterogeneity among families
in complex traits. The numbers of available fami-
lies were also relatively low suggesting that the
weak results were in part related to the lack of
power. In addition, the identified susceptibility loci
were very large encompassing millions of base pairs
often coding for hundreds of genes in the identified
chromosomal regions, and linkage as a method was
unsuitable for further narrowing down these large
susceptibility loci. Nevertheless, linkage data have
confirmed the involvement of the HLA Class II
region on chromosome 6p21.3 in MS, even though
the lod score has not reached the level of formal sta-
tistical significance of 3 that is conventionally con-
sidered the lowest threshold suggesting linkage (at
least in mendelian disorders). All other “loci of
interest” had lod scores between 1 and 2 (or below).
Linkage as a hypothesis free approach confirmed
that multiple loci play a role, MS is a polygenic dis-
ease, and the HLA Class II region may have the
strongest influence on disease susceptibility. Based
on the analyses of HLA allele sharing by descent in
sib pairs, the HLA region was estimated to define
20-60% of genetic susceptibility in MS29, 34, 39. 
Conclusions of the microsatellite-based linkage
analyses were further confirmed in a single
nucleotide polymorphisms (SNP) – based linkage
study that used 4500 SNP markers in 750 multiplex
MS families and showed a peak lod score of 11.7 in
the HLA region (SNPs are sequence variations at
certain positions as opposed to the length polymor-
phism of microsatellite repeats; see more specific
definition of SNPs below)40. However, even in this
highly powered SNP-based linkage study, no other
locus showed lod score with genome-wide signifi-
cance. Linkage as a method had clearly reached its
limits in MS, and it was necessary to turn to new
methods based on information from the Human
Genome Project.
SINGLE NUCLEOTIDE POLYMORPHISMS GENOTYPING AND
LINKAGE DISEQUILIBRIUM ANALYSES
Recent explorations of the human genome included
not only full sequence determinations, but also sys-
tematically collected information on genetic varia-
tions by the SNP Consortium Allele Frequency
Project and the HapMap Project41, 42. The SNP and
Hapmap databases are publically available (http://
www.ncbi.nlm.nih.gov/snp/ and http://hapmap.
ncbi.nlm.nih.gov/). We have learnt from data of the
Human Genome Project (http://www.ncbi.nlm.
nih.gov/genome) and the SNP and Hapmap studies
that the human genome is composed of 3.2 billion
base pairs, and comparing the genomic sequences
of any two today living individuals, 99.9% similari-
ty may be observed. The 0.1% differences come
from genetic variations, the most frequent of them
being the single nucleotide polymorphisms (SNPs).
As the name suggests, alleles of SNPs are defined
by single nucleotide variations at a given position
(at such position, pyrimidine-pyrimidine i.e. cyto-
sine/thymine, or purine-purine i.e. adenine/guanine
alternate alleles may be detected; or pyrimidine/
purine alleles i.e. cytosine/adenine, cytosine/gua-
nine, thymine/adenine, thymine/guanine alternates
may also be present). These genetic variations
determine phenotypic differences and susceptibility
to common diseases in the population. The distribu-
tion of SNPs is not even in the genome. Neverthe -
less, roughly one SNP may be expected for every
1000 nucleotides43–45.
SNP alleles align in haplotypes that are chromo-
somal blocks within which recombinations do not
occur during meiosis. An offspring carries one copy
of each chromosome from his/her mother and
father. During meiosis, multiple recombinations or
crossing over exchanges occur between the homol-
ogous maternal and paternal chromosomes. These
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exchanges result in mosaics of maternally and
paternally derived chromosomal blocks in the off-
spring’s chromosomes (Figure 1A). SNP alleles are
in linkage disequilibrium (LD) with each other
within particular chromosomal blocks, and these
chromosomal blocks, also called haplotypes, tend
to be inherited together from parents to offspring
through generations in the population. The size dis-
tribution of haplotype blocks is related to the popu-
lation/meiotic history and thus, characteristic of
each ethnic group. Older populations (e.g. African
Yorubans) are characterized by shorter haplotype
blocks than younger populations (e.g. Asians and
Europeans). The longer the population history, the
more meiosis and more recombinations occurred
through subsequent generations, which resulted in
shorter haplotype blocks in the chromosomes of the
today representatives of that population41. 
Haplotypes, defined by specific allelic combina-
tions in a population may facilitate performing
research studies. When a disease-causing mutation
arises, it does so within a haplotype (Figure 1B).
Defining first the haplotype that is associated with
a disease may subsequently help to narrow down
and identify the specific disease-causing mutation
or SNP variant within that haplotype. Since the
marker allele is in LD with the disease allele, this
method is often referred to as LD mapping. LD
mapping has been extensively used for exploring
genetic susceptibility in complex trait disorders. 
Our three-stage study focused on the 17q11
chromosomal region in MS exemplifies how this
strategy works. We selected the 17q11 region
because 1) A meta-analysis of three genome scans
revealed the highest nonparametric linkage score
(NPL=2.58) at 17q1146 and two case-control stud-
ies suggested involvement of this region in MS47, 48;
2) This chromosomal region encodes two clusters
of β-chemokine ligands (or CC chemokine ligands -
CCLs) within a 1.85 MB chromosomal segment of
17q11; CCLs have been implicated in the pathogen-
esis of MS as well as in experimental autoimmune
encephalomyelitis (EAE, an induced inflammatory
demyelinating model of MS)49; and 3) EAE studies
showed that mouse and rat chromosomal regions
synthenic to the human 17q11 confer susceptibility
to EAE (just like 17q11, the synthenic mouse and
rat chromosomal regions also encode CCL gene
clusters)50, 51. 
In the first phase of this three-parts study, we
genotyped 32 SNPs within 17q11, in 1085 individ-
uals of 257 MS families52. The results suggested
Ideggyogy Sz 2014;67(9–10):309–321. 313
Figure 1. SNP haplotypes and disease-relevant variants.
A. Recombination during meiosis. During meiosis,
recombinations occur between homologous maternal and
paternal chromosomes and result in recombinant chro-
mosomes in the offspring. B. Haplotypes. SNP haplotypes
are defined by certain alleles of SNPs which are in LD
with each other. These allele combinations or haplotypes
tend to be inherited together in the population, because
recombinations do not occur within the haplotypes.
Disease causing mutations develop within haplotypes or
chromosomal blocks, making it possible to identify first
the disease associated haplotypes followed by the identi-
fication of the disease relevant variant within that haplo-
type
BA
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SNP alleles and haplotypes within the CCL2,
CCL11-CCL8-CCL13, CCL3 and CCL15 genes
likely relevant to MS. In the second phase, we geno-
typed 232 SNP markers in the same region in a new
set of 1369 individuals in 361 MS families. This
second study confirmed and refined the previously
suggested associations53. In the third phase, we
selected from the MS-associated haplotypes one
within the CCL3 gene, and sequenced this haplo-
type along with its flanking regions to reveal which
polymorphisms (SNP allele) have the strongest
association with MS and likely be the disease-rele-
vant variant within that haplotype. Sequencing
revealed several new SNPs within this CCL3 hap-
lotype, which we genotyped in an independent set
of MS cases and controls, and thus defined which
variant within this haplotype showed the strongest
association with the disease54. This three-stage
study based on LD analyses first identified MS-
associated SNP variants and haplotypes within spe-
cific genes at 17q11, which were then confirmed
and refined in the second study. We postulated that
these marker variants were in LD with specific dis-
ease-relevant variants. Therefore, in the third study
we defined the SNPs that showed the strongest
association within one of the MS-associated haplo-
types (in the CCL3 gene), which likely have direct
relevance to the disease. This study shows how we
may get sequentially closer from a large (1.8 mil-
lions of base-pairs) chromosomal susceptibility
region (17q.11) to a few hundred-base-pair size
haplotype and then to single disease-relevant genet-
ic variants by relying on LD. 
GENOME-WIDE ASSOCIATION STUDIES
Similar to the above outlined 17q11 analyses,
genome-wide association studies (GWAS) studies
also rely on LD between a study-marker and a dis-
ease-relevant variant to define susceptibility in a
complex trait, but instead of characterizing a select-
ed region, the entire genome is scanned to reveal
the genetic architecture of a disease. Typically from
3-6X105 to a few millions of markers are tested in
large patient (case) and control populations to iden-
tify allele frequency differences suggesting associa-
tions with the disease. This association-based
approach is far more powerful to reveal disease
variants with small effects than the method of link-
age. However, some key requirements need to be
satisfied in order to yield a successful outcome in
genome-wide association analyses: 1) Genome-
wide significance cannot be reached if the sample
size is inadequate and the signal of the disease gene
is small. To minimize the risk of false negative
observations (Type I error), inclusion of large num-
bers (typically several thousands) of study subjects
may be necessary which may only be available
through collaborations within consortia; 2) Because
of the ethnic-specific nature of SNP frequency dis-
tributions, matching ethnically the control and the
patient populations is a key requirement to avoid
population stratification and false positive observa-
tions (Type II error); 3) Due to the large numbers of
markers, corrections for multiple testing are neces-
sary. However, using overly stringent corrections, a
genome-wide significance may get lost (Type I
error). Therefore, proper selection of methods to
correct for multiple testing and taking LD between
markers into consideration (acknowledging that
associations with the markers within a haplotype are
not independent) are necessary55, 56.  
The first highly powered MS GWAS study with
dense coverage of the entire genome was published
in 200757. This study used DNA microarray tech-
nology to test almost 335,000 SNP markers in over
12,000 total subjects in MS trio families and case-
control cohorts in the initial and replication study
parts. The results showed that two SNPs within the
interleukin-2 receptor alpha gene (IL2RA)
(P=2.96×10-8), a nonsynonymous SNP in the inter-
leukin-7 receptor alpha gene (IL7RA) (P=2.94×10-
7) and multiple SNPs in the HLA-DRA locus
(P=8.94×10-81) were associated with MS. Numerous
studies accompanied or followed this GWAS to
confirm and refine the involvement of the IL2RA
and the IL7RA variants in MS susceptibility, and to
sort out their biological significance58–63. It was
shown that the MS-associated SNP variant in the
IL7RA gene regulates alternative splicing by aug-
menting the exonic silencer of exon 6. Skipping of
(splicing out) exon 6 increases the soluble and
decreases the membrane-bound isoform of the
receptor, which impacts on T and B cell develop-
ment and differentiation59. A similar influence of
the MS-associated IL2RA variant on the soluble vs.
membrane-bound forms was also suggested56. A
SNP variant in the CD58 gene, encoding the LFA-3
costimulatory molecule, was negatively associated
with MS (Odd ratio or OR=0.82), suggesting that
this allele exerts protective effect64. The protective
allele was shown to increase CD58 expression,
which upon engagement with its CD2 receptor, up-
regulates the expression of transcription factor
FoxpP3. Increased FoxP3 is associated with an
enhanced function of CD4+CD25high Treg cells that,
as indicated above, are defective in MS patients64. 
In addition to these well characterized MS-asso-
ciated non-HLA genes, further non-HLA MS-sus-
ceptibility variants were revealed by analyses of
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data from focused or comprehensive SNP genotyp-
ing60, 64–69. 
As of today, 7 independent GWAS studies have
been reported in MS, but numerous studies with
narrower scopes were also published57, 63, 68, 70–75.
The HLA and non-HLA genetic variants associated
with MS in the 7 GWAS are listed in Table 1.29.
The International Multiple Sclerosis Genetics
Consortium and the Wellcome Trust Case Control
Consortium 2 [WTCCC-2]76 reported a GWAS on
9772 cases of European descent collected by 23
groups in 15 countries. This study replicated 23 of
26 previously known MS-associated variants and
identified 29 novel susceptibility variants. Within
the HLA DR1 gene, this group refined the risk alle-
les and showed that certain HLA A alleles may pro-
vide protective effect in MS. 
Meta-analyses of GWAS data can be controver-
sial, because it mixes results from various ethnic
groups, but since both cases and controls are group-
wise included, it can also be extremely powerful.
Two meta-analyses of MS GWAS studies refined
previous discoveries and added new susceptibility
markers to the previous lists68, 77. They also revealed
that the investigated variants altered gene expres-
sion in peripheral blood mononuclear cells and were
involved in inflammatory processes suggesting
their functional significance in MS68, 77. 
A proportion of susceptibility markers identified
in MS overlaps with those found in other complex
trait disorders such as rheumatoid arthritis, Crohn’s
disease, Type I diabetes, celiac disease, SLE and
psoriasis, suggesting that these variants define an
overarching autoimmune trait and are not specific
for MS (reviewed in 29). Some of these autoim-
mune variants are located within genes of PTP22,
IL23R, NRXN1, KIAA1109, EPHA7, TRIM27,
TNFAIP3, TNKS, and C20orf4229. 
There are a few technical issues to take into con-
sideration concerning GWAS studies. It is impor-
tant to keep in mind that not all the MS-associated
SNP alleles have direct relevance to the disease. As
outlined above, some of these alleles may only be
in LD with a disease variant. In addition, most of
the GWAS studies used microarray technologies
that preferentially test common SNP variants (pop-
ulation frequency >5%)29. Therefore, evolutionarily
newer, rare variants have not been systematically
interrogated in MS by GWAS, and therefore, non-
array-based, focused association studies, even
though smaller than GWAS (such as our 17q11
scan), may reveal information missed by GWAS.
The challenge is to identify methods suitable for
testing not only common but also rare variants with
genome-wide coverage for the refinement of cur-
rent knowledge concerning the genomic landscape
in MS and other complex diseases. 
PATHWAY ANALYSES
The above discussed hypothesis-free GWAS
(Table 1.) reveal that the identified variants are
mainly within genes of immune response and there-
by support without preconceived assumption that
immune-mediated pathways play key roles in the
development of MS. This finding has major signifi-
cance, since the views concerning a primary
immune vs. CNS etiology of MS have long been
debated78, and objective observations to unequivo-
cally support either position had been missing. 
Formal pathway analyses of the MS-associated
genetic variants identified by various GWAS stud-
ies have been conducted with similar outcomes. In
the study by the WTCCC-276, statistical analyses
were performed to identify genes with similar func-
tion. First, the authors identified the nearest gene to
the SNP of interest in each region of association and
used the so called Gene Ontology (GO) database to
test whether or not the groups of nearest genes were
enriched for functional relatedness. This analysis
showed significant enrichment for lymphocyte
function, particularly for T cell proliferation and
activation, T helper cell differentiation, and inter-
cellular immune communication through cell sur-
face receptors and cytokines, and signal transduc-
tion. This study, however, did not find evidence for
genetic associations with clinical course, disease
severity, month of birth or gender. 
More recently, a protein-interaction-network-
based pathway analysis (PINBPA) of data from two
large MS studies (WTCCC2 and meta2.5,)68, 76 was
reported, which involved a total of 15,000 cases and
31,000 controls75. PINBPA is even a more advanced
and more powerful analytical approach than the pre-
viously used pathway analysis methods. This study
assumed that even modestly associated genes may
participate in biologically relevant pathways, and
therefore considered all genes with p<0.05 after p-
values were computed from individual SNP-wise
summary-level data using a special program
(VEGAS) (This low threshold of significance needs
to be viewed in the context of GWAS where a
genome-wide significance of p<10-8 is typically
required assuming independence among markers).
After this more liberal inclusion of candidate genes,
another program (the so called Manhattan visuali-
zation plot) was used to define association peaks.
The distribution of nominally associated loci was
largely identical in the two studies (WTCCC2 and
meta2.5)68, 76. The association blocks matched the
Ideggyogy Sz 2014;67(9–10):309–321. 315
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boundaries of the association
regions of the 57 MS susceptibility
loci76. Then, the authors combined
statistical evidence of gene associa-
tion and physical evidence of pro-
tein-protein interaction. The
PINBPA analyses revealed that
protein products of genes that
showed genome-wide significance
were more likely to physically
interact and to belong to the same
or similar pathways. The sub-net-
works or modules of genes (and
their protein products) enriched
with nominally associated loci
were also investigated within each
of the two studies (WTCCC2 and
meta2.5)68, 76. These analyses
demonstrated that the modules
were more likely to include genes
with “bona fide” susceptibility
variants and identified several new,
biologically relevant candidates75.
Finally, to define biological signifi-
cance of associated and candidate
genes, the group conducted Gene
Ontology analyses, which revealed
three main categories of biological
processes: leukocyte activation,
apoptosis and positive regulation of
macromolecular metabolic process-
es. Another, the so called KEGG
pathway analysis highlighted the
JAK-STAT signaling pathway,
acute myeloid leukemia, and T cell
signaling pathways. (KEGG
[Kyoto Encyclopedia of Genes and
Genomes] is an assembly of online
databases of genomes, enzymatic
pathways and biomaterials. The
PATHWAY database of KEGG
includes networks of intracellular
molecular interactions in various
organisms). Tissue specificity
analyses suggested that 2/3 of the
genes were highly expressed in
immune cells, and half of the genes
were expressed in the CNS.
However, further analyses exclud-
ed the involvement of a neural
pathway in MS. These complex,
multi-step analyses provided strong
evidence to further support the
involvement of immune pathways
in MS75.
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MITOCHONDRIAL GENOME
The mitochondrial (mt)DNA is a small, extra-
nuclear part of the genome, and often omitted from
reviews of MS genetics/genomics. As the author of
this paper carried out the first comprehensive
mtDNA polymorphism and full sequence analyses
in MS cases and controls, and the investigations of
nuclear and mtDNA-defined variants of Complex I
in MS families, the results are briefly discussed
here11, 79–81. The involvement of mtDNA in MS sus-
ceptibility was suggested by the observations that
MS occurred more frequently than expected by
chance in Leber’s Hereditary Optic Neuropathy
(LHON) pedigrees, MS also co-occurred intra-indi-
vidually with LHON in some patients, and subse-
quently, primary LHON mutations were detected in
some MS patients (Reviewed in 11). Our compre-
hensive analyses of mtDNA excluded, however, the
involvement of mtDNA mutations with pathogenic
significance in MS, but revealed the associations of
certain mtDNA haplotypes and variants with the
disease79, 80. These findings were later reproduced
by several groups (reviewed in 11). We also found
that variants within nuclear and mtDNA-encoded
genes of Complex I are associated with MS and
likely interact with each other at the protein level81.
Complex I is the first enzyme complex involved in
mitochondrial oxidative phosphorylation and
encoded by 38 nuclear and 7 mitochondrial genes.
We found that the activity of Complex I is negative-
ly affected by oxidative damage developing second-
ary to inflammation in MS lesions10. However, we
were unable to detect mitochondrial genetic mark-
ers of phenotypic subgroups of MS. Our compre-
hensive studies identified mtDNA variants and hap-
lotypes that confer modest risks to the disease, and
revealed that Complex I, a mitochondrial enzyme
with MS-associated genetic variants, also has func-
tional involvement in lesion development. These
studies laid the ground works for establishing that a
mitochondrial mechanism leads to neurodegenera-
tion developing secondary to inflammation in MS.
Conclusion and future directions
Data from genetic and genomic studies have con-
sistently identified the HLA locus as a major sus-
ceptibility locus, and established that HLA defines
more than 50% of genetic susceptibility in MS.
GWAS studies revealed thus far 57 non-HLA sus-
ceptibility variants with moderate and small effects.
These genetic variants are within genes that define
pathways of immune response, intercellular com-
munication, macromolecular metabolic processes,
apoptosis and signal transduction. Additional genes
(and their protein products) may be identified by
approaches that reveal candidates with smaller
effects and by newer genome-wide genotyping
strategies that may capture very rare variants in the
population. Gene ontology and pathway analyses
have greatly facilitated to view genomic results in
functional context. Protein-protein interaction ana -
lyses replicated and confirmed most of the previous
conclusions concerning pathways and networks
defined by GWAS data, and further refined our
knowledge regarding MS pathogenesis. Alto gether,
genomic data, first in MS history, provided objec-
tive evidence to support the immune etiology of the
disease. Studies with narrower focus on selected
chromosomal regions may still be justified to reveal
variants with small effects. Such information may
be relevant to additional MS pathways, and com-
plementary to the GWAS data, if used in the appro-
priate context. MtDNA analyses also complement-
ed the large genome-wide efforts, and identified
genetic variants and functional pathways involved
in the down-stream process of neurodegeneration
developing secondary to inflammation.
A future extension of these investigations will
likely explore as to how environmental factors inter-
act with the genetic susceptibility variants and con-
tribute to immune activation and inflammation.
Gene-environmental interactions can be probed by
methods of epigenetics, which investigate modifica-
tions of histone by biochemical processes (methyla-
tion, acetylation, phosphorylation, ubiquitination
and sumoylation) at certain amino acids, methyla-
tion of CpG sequences within DNA, and microRNA
expression. All these epigenetic processes are
involved in gene expression regulation. The epige-
netic modifications of histones, DNA and
microRNA expression often result from interactions
with environmental factors such as microbial agents,
UV irradiation, toxic molecules, and smoking, pre-
viously identified in MS epidemiologic studies.
While there have been a great number of epigenetic
investigations in MS82–85, none was comprehensive
enough to allow unambiguous conclusions. After the
rewarding outcomes of GWAS studies, epigenetic
approaches may represent the next step to gain fur-
ther insights into the complex etiology of the dis-
ease. Integration of genomic, mitochondrial genetic,
epigenetic and transcriptomic data may provide an
additional dimension to the analyses, and elucidate
not only cross-sectional but also longitudinal aspects
of biological processes important in MS pathogene-
sis. The emphasis on specifying the pathogenesis is
very important for future pharmaceutical discover-
ies and targeting, or for the ultimate goal of prevent-
ing the disease.   
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